OurMission
We're building a rare disease company that is deliberate and purposeful in its approach
We are agile and identify new opportunities to broaden patient access to new and existing medicines
We move quickly and cost-effectively to rapidly commercialise products
We are curious and energetic with a problem-solving mindset
We use new ways of working whenever we can to create value and support scale-up
Our Team
An experienced, entrepreneurial team united by a shared mission to make a measurable difference in rare diseases. Meet the board:
John Irwin
Chief Commercial Officer & Co-Founder
John has more than 25 years of experience in the pharmaceutical industry.
Ahmed Al-Derzi
CEO & Co-Founder
Ahmed is an experienced entrepreneur and business leader.
Dr Kieran Rooney
Non-Executive Director
Kieran brings over 30 years of experience in biopharma.
Values that shape how we work
Compassion, Respect & Humility
We put patients and people first in everything we do. We listen, we learn, and we act with empathy.
Openness & Diversity of Thought
We value different perspectives and believe the best ideas come from inclusive, open collaboration.
Innovation & Challenge
We challenge convention and seek smarter ways to solve problems for the rare disease community.
Collaboration & Meaningful Work
We work together with purpose, celebrating what each person brings to our shared mission.
Therapeutic Areas
We are focused on identifying and addressing patient needs and are agnostic to a medicine's modality, mechanism or novelty.
Antifibrotic
Fibrotic diseases are conditions in which the body produces excessive scar tissue in organs.
Approximately 180,000–270,000 people in Europe are living with antifibrotic illnesses.
We are focusing on supporting patients initially with Idiopathic Pulmonary Fibrosis (IPF).
Transthyretin Amyloid Cardiomyopathy
ATTR-CM is a progressive form of cardiomyopathy caused by misfolded transthyretin protein.
ATTR-CM affects an estimated 100,000–150,000 people across Europe.
Our focus is to improve diagnosis and accelerate equitable access.